QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus.

Nicola EdwardsAlexander W W Langford-SmithBenjamin J ParkerIan N BruceJohn A ReynoldsM Yvonne AlexanderEoghan M McCarthyFiona L Wilkinson

Published in: Lupus science & medicine (2018)

QRISK3 captures significantly more patients with SLE with an elevated 10-year risk of developing CVD, which is associated with measures of endothelial dysfunction; EMVs and systolic BP. The adoption of QRISK3 will enhance management of CVD risk in patients with SLE for improved outcome.

Keyphrases

systemic lupus erythematosus
cardiovascular disease
blood pressure
disease activity
metabolic syndrome
loop mediated isothermal amplification